About 75,970 results

ALLMedicine™ Multiple Sclerosis Center

Research & Reviews  23,399 results

Diffusion-derived parameters in lesions, peri-lesion, and normal-appearing white matter...
Journal of Cerebral Blood Flow and Metabolism : Official ... van der Weijden CW, van der Hoorn A et. al.

Jun 28th, 2022 - Neuronal damage is the primary cause of long-term disability of multiple sclerosis (MS) patients. Assessment of axonal integrity from diffusion MRI parameters might enable better disease characterisation. 16 diffusion derived measurements from dif...

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosph...
Journal of Visualized Experiments : JoVE; Cheng L, Su L et. al.

Jun 28th, 2022 - Lysophospholipids (LPLs) are bioactive lipids that include sphingosine 1-phosphate (S1P), lysophosphatidic acid, etc. S1P, a metabolic product of sphingolipids in the cell membrane, is one of the best-characterized LPLs that regulates a variety of...

IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple scle...
PloS One; Petržalka M, Meluzínová E et. al.

Jun 28th, 2022 - The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed....

Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPR...
Multiple Sclerosis and Related Disorders; Bove R, Hellwig K et. al.

Jun 27th, 2022 - Most disease-modifying therapies (DMTs) approved for the treatment of multiple sclerosis (MS) are not recommended during pregnancy, and discouraged while breastfeeding. However, discontinuation of some DMTs before pregnancy can leave women vulnera...

Fatigue in multiple sclerosis is associated with socioeconomic factors.
Multiple Sclerosis and Related Disorders; Broch L, Flemmen HØ et. al.

Jun 27th, 2022 - Fatigue is one of the leading causes of reduced quality of life and inability to work in people with multiple sclerosis (pwMS). Currently, no treatment effectively ameliorates fatigue. We still know little about what causes fatigue and which facto...

see more →

Guidelines  16 results

Supporting the Role of Parenting for People with Multiple Sclerosis: A Guide for Clinic...
Archives of Physical Medicine and Rehabilitation; Rider JV, Selim J

Jun 18th, 2022 - Supporting the Role of Parenting for People with Multiple Sclerosis: A Guide for Clinicians.|2022|Rider JV,Selim J,|

Vision Problems in Multiple Sclerosis.
Archives of Physical Medicine and Rehabilitation; Costa SL, Pandey K et. al.

Sep 29th, 2020 - Vision Problems in Multiple Sclerosis.|2020|Costa SL,Pandey K,Hrdina J,Rondon M,Devos H,|

Serum neurofilament light as a biomarker in progressive multiple sclerosis.
Neurology Kapoor R, Smith KE et. al.

Jul 18th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...

Practical Sleep Information for People With Multiple Sclerosis.
Archives of Physical Medicine and Rehabilitation; Siengsukon C, Karahan AY et. al.

May 14th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|

Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis...
Multiple Sclerosis and Related Disorders; Lebrun C, Vukusic S et. al.

Jun 5th, 2019 - To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have b...

see more →

Drugs  389 results see all →

Clinicaltrials.gov  2,551 results

Pathological Basis of MRI Signal Changes in Multiple Sclerosis

Jun 24th, 2022 - Objective: The goal of this protocol is to understand how the pathology of multiple sclerosis (MS) relates to its evolution over time as observed through neuroradiological, clinical, and biological data collection in vivo. Study population: This s...

Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)

Jun 24th, 2022 - The objective of this study is to examine the risk factors and natural course of JCV infection and progressive multifocal leukoencephalopathy (PML). PML is a devastating, demyelinating neurological disease affecting the brain of patients with a co...

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

Jun 24th, 2022 - Objectives. The primary aim of this pilot study is to assess the effects of short-term, high-dose corticosteroid administration on the 12-week evolution of multiple sclerosis lesions with centripetal enhancement pattern on magnetic resonance imagi...

Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility

Jun 24th, 2022 - Objective. The overall objective of this study is to investigate the genetic, immune, and neuroimaging profiles that may increase a person s risk of developing multiple sclerosis (MS) in order to identify and validate predictive biomarkers in popu...

Natural History of Optic Neuritis

Jun 24th, 2022 - Objective The goals of this pilot study are: To assess the degree to which subacute changes in clinical, electrophysiological, and imaging measures can robustly predict retinal neuronal loss 12 months after acute optic neuritis. To construct a com...

see more →

News  3,976 results

Autoimmune disorder drugs top list of meds linked to headache
Randy Dotinga

Jun 23rd, 2022 - DENVER – Monoclonal antibodies, antivirals, immunomodulators, and pulmonary arterial vasodilators top the list of drugs that were most frequently implicated as causes of headaches in a federal side effect database that anyone can contribute to, ac.

Top Medications Most Often Linked to Headache

Jun 23rd, 2022 - DENVER, Colorado — Monoclonal antibodies, antivirals, immunomodulators, and pulmonary arterial vasodilators top the list of drugs that were most frequently implicated as causes of headaches in a federal side effect database that anyone can contrib...

Novel Drug for Relapsing-Remitting MS: New Phase 2 Data

Jun 22nd, 2022 - The novel drug vidofludimus calcium (Immunic Therapeutics) is safe and effective for patients with relapsing-remitting multiple sclerosis (RRMS), new research suggests. Vidofludimus calcium is an investigational oral second-generation selective di...

COVID Vaccination in DMT-Treated MS Patients: New Data

Jun 21st, 2022 - NATIONAL HARBOR, Maryland ― The latest updates on COVID-19 vaccination response among patients with multiple sclerosis (MS) who are treated with disease-modifying therapy (DMT) show that if patients do contract the virus, cases are mild, and serio...

No Clear Answers From MS Drug Discontinuation Trial

Jun 20th, 2022 - NATIONAL HARBOR, Maryland — The first randomized trial to examine whether older adults with multiple sclerosis (MS) can safely discontinue disease-modifying therapy (DMT) after years of being relapse-free failed to deliver a definitive conclusion....

see more →

Patient Education  57 results see all →